GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Long-Term Debt & Capital Lease Obligation

Genscript Biotech (HKSE:01548) Long-Term Debt & Capital Lease Obligation : HK$2,742 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Genscript Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,742 Mil.

Warning Sign:

Genscript Biotech Corp keeps issuing new debt. Over the past 3 years, it issued USD 290.263 million of debt.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Genscript Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,742 Mil. Genscript Biotech's Total Assets for the quarter that ended in Dec. 2023 was HK$26,454 Mil. Genscript Biotech's LT-Debt-to-Total-Asset for the quarter that ended in Dec. 2023 was 0.10.

Genscript Biotech's LT-Debt-to-Total-Asset declined from Dec. 2022 (0.12) to Dec. 2023 (0.10). It may suggest that Genscript Biotech is progressively becoming less dependent on debt to grow their business.


Genscript Biotech Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Genscript Biotech's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Long-Term Debt & Capital Lease Obligation Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.80 60.26 1,157.52 2,374.66 2,742.11

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,157.52 1,688.51 2,374.66 2,633.66 2,742.11

Genscript Biotech Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Genscript Biotech  (HKSE:01548) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Genscript Biotech's LT-Debt-to-Total-Asset ratio for the quarter that ended in Dec. 2023 is calculated as:

LT-Debt-to-Total-Asset (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=2742.114/26454.151
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Genscript Biotech Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech (HKSE:01548) Business Description

Industry
Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Executives
Wang Luquan 2401 A concert party to an agreement to buy shares
Wang Ye 2101 Beneficial owner
Zhang Fangliang 2401 A concert party to an agreement to buy shares
Huang Lili 2202 Interest of your spouse
Hu Zhiyong 2201 Interest of corporation controlled by you
Jin Weihong 2201 Interest of corporation controlled by you
Genscript Corporation 2101 Beneficial owner
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Gns Holdings Limited 2101 Beneficial owner
Hillhouse Capital Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines